Jeffrey Humphrey
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
Jeffrey S.
Humphrey served as President & Chief Medical Officer at Kyowa Kirin Pharmaceutical Development Ltd.
from 2013 to 2019.
He was also Senior Vice President-Drug Development at Kyowa Hakko Kirin Pharma, Inc. in 2012.
Humphrey served as Chief Development Officer at Kyowa Kirin Co., Ltd.
in 2019-2020 and as Chief Medical Officer at Constellation Pharmaceuticals, Inc. in 2020-2021.
He was an Independent Director at Cyteir Therapeutics, Inc. from 2021 to 2023 and Chief Medical Officer at Magenta Therapeutics, Inc. in 2021-2022.
Humphrey received his undergraduate degree from Harvard College and his doctorate from Case Western Reserve University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.10.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Ehemalige bekannte Positionen von Jeffrey Humphrey
| Unternehmen | Position | Ende |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Director/Board Member | 29.11.2023 |
| MAGENTA THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01.08.2022 |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 15.07.2021 |
| KYOWA KIRIN CO. LTD. | Corporate Officer/Principal | 01.06.2020 |
Kyowa Kirin Pharmaceutical Development Ltd.
 Kyowa Kirin Pharmaceutical Development Ltd. Miscellaneous Commercial ServicesCommercial Services Kyowa Kirin Pharmaceutical Development Ltd. engages in developing pharmaceutical products. The company was founded on December 31, 1996 and is headquartered in London, the United Kingdom. | President | 01.08.2019 |
Ausbildung von Jeffrey Humphrey
| Harvard College | Undergraduate Degree |
| Case Western Reserve University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| KYOWA KIRIN CO. LTD. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| Kyowa Hakko Kirin Pharma, Inc. | |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Kyowa Kirin Pharmaceutical Development Ltd.
Kyowa Kirin Pharmaceutical Development Ltd. Miscellaneous Commercial ServicesCommercial Services Kyowa Kirin Pharmaceutical Development Ltd. engages in developing pharmaceutical products. The company was founded on December 31, 1996 and is headquartered in London, the United Kingdom. | Commercial Services |
